San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Visgenx is raising $5,625,266.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Santosh Vetticaden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Visgenx

Visgenx is developing therapeutics to protect against the loss of sight from retinal disorders. Our programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.

To learn more about Visgenx, visit http://visgenx.com/

Contact:
Santosh Vetticaden, President and Chief Executive Officer
408-203-5023
https://www.linkedin.com/in/santosh-vetticaden-md-phd-mba-9bbb972/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved